Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to $175000.0.

  • Pharma's Prepaid Assets fell 5967.74% to $175000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $175000.0, marking a year-over-year decrease of 5967.74%. This contributed to the annual value of $395000.0 for FY2025, which is 8990.38% up from last year.
  • According to the latest figures from Q3 2025, Pharma's Prepaid Assets is $175000.0, which was down 5967.74% from $212000.0 recorded in Q2 2025.
  • Pharma's Prepaid Assets' 5-year high stood at $3.2 million during Q1 2021, with a 5-year trough of $175000.0 in Q3 2025.
  • Its 5-year average for Prepaid Assets is $824526.3, with a median of $395000.0 in 2025.
  • Per our database at Business Quant, Pharma's Prepaid Assets soared by 21115.38% in 2021 and then crashed by 8110.33% in 2022.
  • Over the past 5 years, Pharma's Prepaid Assets (Quarter) stood at $1.7 million in 2021, then crashed by 81.1% to $322000.0 in 2022, then tumbled by 41.61% to $188000.0 in 2023, then skyrocketed by 111.7% to $398000.0 in 2024, then plummeted by 56.03% to $175000.0 in 2025.
  • Its last three reported values are $175000.0 in Q3 2025, $212000.0 for Q2 2025, and $395000.0 during Q1 2025.